FDA Names Tracy Beth Høeg as Acting CDER Director After Richard Pazdur Announces Retirement 
Boeing Secures Multi-Billion Dollar Defense Contracts for F-15IA Jets and E-4B Aircraft Support 
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms 
Pfizer Boosts Bid for Metsera Amid Intensifying Rivalry with Novo Nordisk in Obesity Drug Market 
Nvidia and Groq Strike Strategic AI Inference Licensing Deal 
Star Entertainment Leadership Shake-Up Deepens as CFO and COO Exit Amid Ongoing Restructuring 
Merck Nears Acquisition of Cidara Therapeutics at Significant Premium 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
Pfizer Sues Novo Nordisk Over Alleged Tactics to Block Obesity Drug Competition 
L&F Tesla Battery Supply Deal Value Drops Sharply Amid EV Market Slowdown 
Warner Bros. Discovery Shares Slide Amid Report of Potential Paramount Skydance Lawsuit 
U.S. Backs Bayer in Supreme Court Battle Over Roundup Cancer Lawsuits 
China’s LandSpace Takes Aim at SpaceX With Reusable Rocket Ambitions 
Royalty Pharma Plc (NASDAQ: RPRX) shares rose 1.5% in after-hours trading on Monday after the company announced it had acquired the final portion of PTC Therapeutics’ remaining royalty interest in Evrysdi, a leading spinal muscular atrophy (SMA) treatment marketed by Roche. The transaction strengthens Royalty Pharma’s position in one of the most successful rare disease therapies on the market and provides long-term revenue visibility tied to Evrysdi’s global sales growth.
Under the terms of the agreement, Royalty Pharma will pay $240 million upfront to secure the royalty rights, with the potential for up to an additional $60 million in sales-based milestone payments. Upon completion of the deal, Royalty Pharma will own 100% of the tiered royalty structure on Evrysdi, which ranges from 8% to 16% of worldwide net sales. This acquisition further aligns with Royalty Pharma’s strategy of expanding its portfolio of high-quality, cash-generating biopharmaceutical royalties.
Evrysdi is an orally administered SMA treatment that received FDA approval in 2020 and has since been used by more than 21,000 patients worldwide. The drug generated approximately CHF 1.6 billion, or about $1.9 billion, in global sales in 2024, reflecting 18% year-over-year growth at constant exchange rates. Analyst consensus forecasts Evrysdi sales to reach CHF 2.3 billion, or roughly $2.9 billion, by 2030, highlighting the strong long-term growth outlook for the therapy.
The royalty structure provides increasing upside as sales grow. Royalty Pharma will receive 8% on annual sales up to $500 million, 11% on sales between $500 million and $1 billion, 14% on sales between $1 billion and $2 billion, and 16% on sales exceeding $2 billion. The company is expected to begin receiving the higher royalty rates in the first quarter of 2026, based on Evrysdi sales from the fourth quarter of 2025.
Goodwin and Maiwald acted as legal advisors to Royalty Pharma in connection with the transaction, which further solidifies the company’s exposure to a fast-growing rare disease market.
